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The Trypanosomatidae family, composed of unicellular parasites, causes severe vector-borne diseases
that afﬂict human populations worldwide. Chagas disease, sleeping sickness, as well as different sorts
of leishmaniases are amongst the most important infectious diseases produced by Trypanosoma cruzi, Try-
panosoma brucei and Leishmania spp., respectively. All these infections are closely related to weak health
care services in low-income populations of less developed and least economically developed countries.
Search for new therapeutic targets in order to hit these pathogens is of paramount priority, as no effective
vaccine is currently in use against any of these parasites. Furthermore, present-day chemotherapy com-
prises old-fashioned drugs full of important side effects. Besides, they are prone to produce tolerance and
resistance as a consequence of their continuous use for decades. DNA topoisomerases (Top) are ubiqui-
tous enzymes responsible for solving the torsional tensions caused during replication and transcription
processes, as well as in maintaining genomic stability during DNA recombination. As the inhibition of
these enzymes produces cell arrest and triggers cell death, Top inhibitors are among the most effective
and most widely used drugs in both cancer and antibacterial therapies. Top relaxation and decatenation
activities, which are based on a common nicking–closing cycle involving one or both DNA strands, have
been pointed as a promising drug target. Speciﬁc inhibitors that bind to the interface of DNA-Top com-
plexes can stabilize Top-mediated transient DNA breaks. In addition, important structural differences
have been found between Tops from the Trypanosomatidae family members and Tops from the host.
Such dissimilarities make these proteins very interesting for drug design and molecular intervention.
The present review is a critical update of the last ﬁndings regarding trypanosomatid’s Tops, their new
structural features, their involvement both in the physiology and virulence of these parasites, as well
as their use as promising targets for drug discovery.
 2014 Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc. This is an open
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The family Trypanosomatidae (order Kinetoplastida) comprises
several unicellular ﬂagellated-protozoan parasites responsible for
many human infectious diseases in low-income populations of less
developed and least economically developed countries (WHO,
2008). Two species of the genus Trypanosoma, Trypanosoma brucei
(subspecies gambiense and rhodesiense) and Trypanosoma cruzi, as
well as the different species of the genus Leishmania, are collec-
tively known as the ‘‘tritryps’’. They are responsible for some of
the most harmful neglected diseases that were tackled by WHO
in the 2003 meeting held in Berlin. Human African trypanosomia-
sis, sleeping sickness or Congo trypanosomiasis is a lethal infection
caused by T. brucei, which is transmitted by tse–tse ﬂies (Glossina)
in Sub-Saharan African countries. Sleeping sickness is a biphasic
disease. The ﬁrst phase is clinically characterized by the presence
of fever, headache, joint pain and itching. Whilst in the second
one, which can be lethal if left untreated, the parasite causes anae-
mia and neurological symptoms owing to the aggressive pathogen-
invasion of the host central nervous system (Lejon et al., 2013).
American trypanosomiasis (Chagas disease), caused by T. cruzi in
Central and South American countries, is transmitted by the faeces
of blood-sucking ‘‘kissing bugs’’ of the subfamily Triatominae. In
addition, indirect transmission through blood transfusions or
organ transplantation from infected patients has also been
reported. Chagas disease symptoms may vary during the course
of infection. Local swelling can be noticed in early stages, but dis-
ease chroniﬁcation leads to a cardiomyopathy, which may result in
sudden death. The occurrence of damage in the gastrointestinal
tract is also very common, with the presence of megacolon and
megaesophagus, thereby leading to an inevitable weight loss
(Teixeira et al., 2011). Leishmaniasis is transmitted by sandﬂies
of the genera Phlebotomus and Lutzomyia. Cutaneous leishmaniasis
(CL), whose etiological agent is Leishmania major in the Old World
– among other species – and Leishmania panamensis and Leish-
mania braziliensis in the New World, should be considered the
mildest clinical presentation of this disease. CL presents with ery-
thema, edema and permanent ulcers at the bite site. Although CL is
not fatal, it is extremely disﬁguring when located on the host’s
face. American tegumentary leishmaniasis (also known as mucocu-
taneous leishmaniasis) arises as a consequence of an inadequately
treated New-World CL (WHO, 2007). This clinical form presents
with severe facial disﬁguration, including nose and lips, which
can derive to cancer processes. Last, there is a very aggressive vis-
ceral form of leishmaniasis (VL) produced by Leishmania donovani
in Asia and Leishmania infantum in the countries of the Mediterra-
nean basin. VL produces organ swelling (speciﬁcally targeting liver
and spleen) and may be deadly if left untreated (Ashford, 2000;
Murray et al., 2005; Antinori et al., 2012).
The impact of these diseases can be measured in terms of prev-
alence, fatal outcomes, as well as disability-adjusted life years
(DALYs) lost as a direct consequence of both pathologic effect
and treatments (Goto and Lindoso, 2010). Sleeping sickness is an
infection exclusively concentrated in South-Saharan countries.
Nowadays, this scourge is prevalent in 36 countries, whose ende-
mic infection involves around 60-million people at risk (Aksoy
et al., 2003). The number of reported cases was estimated to be
ca. 10,000 but it represented only one-third of the real infections
occurred in 2009. In addition, an estimated annual DALYs lost of
1.7-million has a profound impact in the economy of thesecountries (Simarro et al., 2011). For its part, Chagas disease has
presence in 18 Central and South American countries with 17 mil-
lion individuals currently infected and 100 million people at risk.
Statistical annual records show the emergence of 41,200 new cases
every year, as well as 12,500 related deaths. Chagas calculated
DALYs reach annual values over 570,000 (Moncayo and Silveira,
2009). Lastly, leishmaniases are prevalent in 98 countries with
presence in four continents (Oceania is the only one free of these
maladies) with approximately 360-million people at risk. Chagas
disease has resurged in USA and Europe due to the incoming tour-
ism and migratory ﬂuxes from prevalent countries of South Amer-
ica (Schmunis, 2007; Gascon et al., 2010). The annual estimation of
leishmaniasis is close to 1.6 new million cases each year, 20,000–
40,000 of which become fatal. Over 50% of the 2-million world-
wide-appraised DALYs is mainly focused in South-East Asia, with
Bihar (India) as the epicenter of Leishmania-related deaths (Alvar
et al., 2012). VL is a re-emerging opportunistic disease in immuno-
suppressed patients owing to three main facts: (i) the immunosup-
pressive effect of drugs used in organ transplantation; (ii) as a
consequence of HIV infections in South-European countries or
(iii) climate change due to global warming (Alvar et al., 2008;
van Griensven et al., 2014; Koltas et al., 2014).
Although prevention is considered the best approach to ﬁght
against these diseases, any possible vaccine is in a very early stage
of development. The main reason is that these infections cause a
deregulation of the host immune system. In fact, it has been shown
that both human patients, as well as experimental animals,
become susceptible to infections caused by these pathogens when
Th1/Th2 balance shifts toward Th2-mediated humoral immunity
(Alexander and Bryson, 2005). However, when there is a shift
toward Th1-dominant immune responses the host becomes resis-
tant and develops (life-span) natural immunity against re-infec-
tion. Nowadays, some new therapies take advantage of this
circumstance to treat these infectious diseases by means of Th1
stimulants or auto vaccines developed from infected hosts. How-
ever, these promising approaches are being only developed for
Leishmania-infected dogs but not for humans, making chemother-
apy the most feasible alternative against these neglected tropical
diseases (NTDs) at present (for a comprehensive review see:
Palatnik-de-Sousa, 2012).
Current chemotherapy against these diseases was developed
many years ago, is plenty of toxic side effects and it often requires
parenteral treatments. These inconveniences make the use of this
chemotherapy in ﬁeld conditions difﬁcult, and since the adminis-
tration of repeated doses is needed, the appearing of relapses is
extremely frequent due to a poor adherence to treatments
(Leprohon et al., 2011). African trypanosomiasis is a good example
of these statements. Pentamidine (an aromatic diamidine) and sur-
amin are the chosen drugs against the ﬁrst blood-stage infection
(Burri, 2010). However, when the neurological phase is established,
only arsenicals (melarsoprol) or the ornithine decarboxylase sui-
cide inhibitor eﬂornithine can ameliorate the symptoms (Lutje
et al., 2013). Recently, the combination of nifurtimox and eﬂorni-
thine has prompted the change from the old-fashioned melarso-
prol to the best treatment available (Simarro et al., 2012). For the
Chagas disease, the current pharmacopoeia is reduced to two
drugs, nifurtimox and benznidazole, with a 60–90 days long treat-
ment and with noticeable side effects (Rassi et al., 2010).
First choice drugs against leishmaniases are old-fashioned pen-
tavalent antimonium-based drugs (Glucantime and Pentostam),
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all over the World (Balaña-Fouce et al., 1998). These drugs have
several ﬂaws, including the need of parenteral administration,
the occurrence of many undesirable side effects, as well as the
appearing of resistances due to the over-usage (Croft and Olliaro,
2011). Drug combinations of antimonials with allopurinol (a xan-
thine oxidase inhibitor) very much improve the curative outcomes
(Manna et al., 2009). In a second instance, macrolide antibiotics
such as Amphotericin B, are a good alternative to the former com-
pounds (Monge-Maillo and López-Vélez, 2013). This antibiotic for-
mulated in liposomes (AmBisome) has resulted in a good therapy
against VL, but it is extremely expensive for developing countries
and requires intravenous administration (Mohamed-Ahmed et al.,
2012). Lipid-ether compounds – miltefosine and edelfosine – are
promising oral drugs ﬁrst synthesized as anti-tumourals but with
potent anti-leishmanial effect (Bhattacharya et al., 2007; Berman,
2008). For its part, paromomycin – an aminoglycoside antibiotic
– has been approved in 2006 in India against VL (Sundar et al.,
2007). These compounds require repeated dosing during 20 days
or more, and with the exception of miltefosine, they must be par-
enterally administered to the patients.
At this point, the need of new drugs against these diseases is
clearly justiﬁable (Barrett and Croft, 2012). However, since NTDs
mostly affect low-income countries, the expectable economic prof-
its of the big pharmaceutical trusts are negligible compared to
those obtained with other pathologies of the more developed
World. Therefore, basic academic research groups have assumed
new drug target discovery and drug design research. Interestingly,
drug discovery initiatives (i.e., DNDi), promoted by world-wide
NGOs and supported by public and private funds are aimed to
eliminate NTDs during the current decade. Meanwhile, Glaxo
Smith Kline has done the economic effort of offering thousands
of compounds from different drug libraries to be tested by basic
research groups in order to ﬁnd new hits against NTDs pathogens.
Within the novel targets for drug intervention, DNA topoisome-
rases (Top) have attracted attention since their discovery. The role
played by Top in cell physiology is of paramount importance and
since the beginning many research groups pointed to these
enzymes as putative targets against proliferative processes. This
is the reason why some Top inhibitors are being marketed against
cancer (Pommier et al., 2010) or as promising antiparasitic drugs
(Das et al., 2008; García-Estrada et al., 2010).
In the present review we update novel information about Top
enzymes in trypanosomatids, making special emphasis in the novel
ﬁndings on their peculiar structure as well as in the molecules used
to target them.2. DNA topoisomerases
Since the length of the DNA helix containing the genetic infor-
mation of an organism is several millions times longer than the
size of the cellular nucleus, it is a physical pre-requisite to fold it
thousands of times in order to ﬁt it inside this organelle
(Annunziato, 2008). DNA packaging can be solved by simple fold-
ing of the circular chromosome in prokaryotic organisms, or can
be condensed around nucleosomes, where histones play a key role
in gene expression and structure of eukaryotic chromosomes. Try-
panosomatids are ancient eukaryotes that contain a unique disc-
shaped extranuclear DNA called kinetoplast inside their single
mitochondrion. Adjacent to the ﬂagellar basal body there is an
intricate mesh of thousands of interlocked DNA rings called mini-
and maxicircles that represents 10 to 20% of the total DNA in the
cell (Shapiro and Englund, 1995; Chen et al., 1995a). Minicircles
are the most abundant form in kDNA (5.000–10.000 molecules
per cell). They are circular DNA molecules with a length perimeterof 100–2500 bp encoding guide RNAs involved in editing mito-
chondrial nascent RNAs (Stuart and Panigrahi, 2002). Maxicircles
are bigger in perimeter – 30,000–50,000 bp – but less abundant
than minicircles – 50 copies per cell. Maxicircles are the equivalent
of mitochondrial DNA from other eukaryotes, as they codify mito-
chondrial proteins, ribosomal RNA and tRNAs (Shlomai, 2004).
Replication of kDNA occurs synchronously with genomic DNA dur-
ing cell division. kDNA components must be decatenated from the
network before their DNA replication and then catenated again to
the nascent mesh when this process is ﬁnished (Liu et al., 2005).
DNA replication from both mini- and maxicircles takes place in
theta (h)-shaped intermediaries, where Top play a key role
(Jensen and Englund, 2012). Since kinetoplast is unique to trypan-
osomatids, it has been pointed as an important target for drug
discovery.
DNA appears in nature as underwound form, acquiring a com-
pact negatively supercoiled organization that is not accessible to
most physiological cell processes when needed. For this reason,
during DNA replication or transcription to RNA, as well as during
DNA repair, DNA supercoils should be resolved to a more relaxed
form that permits access to polymerases, transcriptional factors
or DNA repair proteins. Top are the proteins responsible for relax-
ing supercoiled DNA introducing breaks in single or both strands of
the double helix (Champoux and Dulbecco, 1972). At this moment,
DNA can rotate freely alleviating the tension accumulated by
supercoiling, powering the rotation of one strand over the other.
This task can be fuelled by ATP hydrolysis or not. Since these
enzymes are molecular machines, a support of energy should be
necessary to exert the mechanical function. According to these
characteristics; the number of DNA strand breaks introduced and
the requirement of metabolic energy, Top are divided into two
Families. Type I Top (TopI) are ATP-independent enzymes that
break one DNA strand, whereas Type II Top (TopII) need ATP
hydrolysis to break both DNA strands (Champoux, 2001). Differ-
ences in the mode of action suppose differences in changes intro-
duced in DNA topology. TopI are solely involved in the relaxation
of supercoiled DNA (Cretaio et al., 2007). TopII, however, are not
only involved in supercoiled DNA relaxation, but they are also
implicated in the catenation/decatenation and knotting/unknot-
ting of complex DNA topological networks (for reviews see:
Wang, 1998, 2002, 2009; Champoux, 2001; Forterre et al., 2007;
Pommier et al., 2010).
TopIA was considered, since long time ago, as a prokaryotic-
borne enzyme that resolves positive supercoils through the tran-
sient covalent binding to the 50-end of the broken DNA strand fol-
lowed by passage and rejoining (Corbett and Berger, 2004).
Regardless TopIA, TopIB is a true Mg2+-independent eukaryotic
enzyme that introduces both positive and negative supercoils,
establishing a temporary covalent bond to the 30-end of cut DNA
releasing a 50-OH free end (Cheng et al., 1998). The catalytic Tyr
at the active site of TopIB introduces a nucleophilic attack on a
phosphate group of the nucleotide chain, creating a transient phos-
phodiester bond with the broken DNA strand (Stewart et al., 1998;
Pommier, 2009). This allows TopIB to change the linking number
(Lk) in multiples of 1 (n), unlike TopIA, which introduces changes
strictly in steps of one in the Lk of a single-stranded circular DNA
(Lindsley, 2005).
TopII are multimeric proteins that break both DNA strands
fuelled by the hydrolysis of ATP. TopII bind transiently to the 50-
ends of both DNA strands relaxing positive and negative supercoils,
changing the Lk in steps of +2 (Watt and Hickson, 1994). The tran-
sient break at both DNA strands permits the passage of another
duplex through the gap and subsequent rejoining. TopII enzymes
relax positively supercoiled DNA, but also have additional catena-
tion/decatenation and knotting/unknotting activities that make
them needed for chromosomal segregation in the nucleus and for
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ing cell division (Chen et al., 1995b).
A common feature to all Top enzymes is the presence of a Tyr
residue in the catalytic site of the enzyme (Champoux, 2001). Tyr
is the amino acid that produces a nucleophilic attack to the phos-
phodiester DNA backbone introducing a transient covalent bond
with the enzyme. This transient bonding has been exploited to
design compounds able to target it. Since the time required to reli-
gate cleaved DNA is extremely short, many compounds act stabi-
lizing this enzymatic step introducing an enzyme-DNA adduct
that undergoes irreversible damage (Hsiang et al., 1985). When
the replication fork collides with one of these stabilized complexes,
a double-strand break can be produced, starting the irreversible
fragmentation (Hsiang et al., 1989). Since the stabilization of
DNA-Top complexes can have a natural origin, eukaryotic cells
have developed a DNA repair systems that act removing these
tyrosyl-DNA bonds. Tyrosyl-DNA-phosphodiesterase-1 (TDP1) has
been regarded as a potential therapeutic co-target of TopIB
(Dexheimer et al., 2008; Banerjee et al., 2010).
A full set of Top enzymes is currently available in the TriTryp
Genome database http://tritrypdb.org/tritrypdb/; (i) nuclear TopIB
and TopIIA enzymes involved in DNA replication and repair that
have been fully described as putative drug targets; (ii) mitochon-
drial TopIA and TopII that have been described closely linked to
kDNA replication; (iii) two putative members of the TopIA subfam-
ily TopIII (a and b) involved in resolving DNA entanglements that
can arise during DNA recombination (Table 1).
2.1. Type IB topoisomerases
Unlike other enzymes characterized to date, kinetoplastid TopIB
is a heterodimer (Reguera et al., 2008). The ﬁrst description was
done in L. infantum where the functional bisubunit enzyme was
composed of a large (L) subunit of 635 amino acids with a MW
of 73 kDa (LiTopIL), which contains the N-terminal and core
domains, and a small (S) subunit of 262 amino acids with a MW
of 28 kDa (LiTopIS), which retains the Tyr catalytic residue. Genes
encoding these proteins are located on different chromosomes in
the leishmanial genome (Villa et al., 2003). In this very year, similar
results were published in African trypanosomes using a classical
platform of protein puriﬁcation. However, a controversy about
the oligomeric status (L2S2) is still under debate (Bodley et al.,
2003). It seems that this unique genomic organization, in which
the genes encoding both TopIB protomers are located on different
chromosomes, occurs solely in trypanosomatids (Reguera et al.,
2006).
Multiple alignments of DNA sequences and X-ray analysis of a
co-crystal containing a truncated LdTopIB bound to nick double
stranded DNA at a resolution of 2.27 Å, permitted the identiﬁcation
of speciﬁc protein domains in the leishmanial enzyme (DaviesTable 1
Tritryps Top-encoding genes annotated into GeneDB database (http://www.gened-
b.org/Homepage). TopIA, TopIB (large and small subunits), TopII and TopIII genes
from different species: L. major Friendlin, T. brucei 927 and T.cruzi.
Protein L. major Friendlin T. brucei 927 T. cruzi
GeneDB database
TopIA LmjF21.0125 Tb927.10.1900 TcCLB.510121.160
TopIB (L) LmjF34.3440 Tb927.4.1330 TcCLB.508693.20
TopIB (S) LmjF04.0060 Tb927.9.6940 TcCLB.506625.110
TopII LmjF28.2280 Tb927.11.11550
Tb927.11.11560
TcCLB.508699.10
TcCLB.509203.70
mtTopII LmjF.15.1290 Tb927.9.5590 TcCLB.508277.370
TopIII LmjF28.1780
LmjF36.3200
Tb927.11.9170
Tb927.11.9520
TcCLB.510901.100
TcCLB.511589.120
TcCLB.508851.170et al., 2006). The large LdTopIL subunit contains a short and poorly
conserved N-terminal domain, whose function has not yet been
clariﬁed so far. The central core domain conserves a high homology
with other TopIB proteins (Stewart et al., 1996; Cretaio et al.,
2007). It contains several amino acids interacting with DNA; i.e.,
Arg314 (Arg488 in the human enzyme), Lys352 (Lys532 in the
human enzyme), Arg410 (Arg590 in the human enzyme) and
His453 (His632 in the human enzyme) (Diaz-González et al.,
2008). Finally, this subunit displays a C-terminal extension, which
lacks homology with other ortholog proteins (Diaz-Gonzalez et al.,
2007a). The small LdTopIS subunit contains a long and non-con-
served N-terminal extension enriched in Ser residues, which is sus-
ceptible of post-translational phosphorylation. However, the C-
terminal domain conserves high homology with the SKINY signa-
ture, where Tyr222 (Tyr723 in human enzyme) is the ﬁfth amino
acid of the catalytic pentad that plays a role in the nucleophilic
attack to DNA. The functionality of these amino acids in the leish-
manial enzyme has been conﬁrmed by single site mutation analy-
sis and expression in a TopIB-null yeast mutant (Diaz-Gonzalez
et al., 2007b) (Fig. 1A).
However, the 3D model obtained from the X-ray analysis fails in
describing the linker domain, a poorly conserved region that con-
nects the core and C-terminus end, because it was removed to pre-
pare the crystal (Davies et al., 2006). The linker domain is not
merely a connector but it contributes to both DNA binding and
sensitivity to TopIB poisons, probably increasing the rigidity of
the structure and slowing down the rotation process prior to the
religation of the cleaved DNA strand (Stewart et al., 1997). A recent
study has disclosed the regions of both subunits that interact to
each other to constitute a functional linker in Leishmania (Prada
et al., 2012). Using a predictive 3D model combined with a sequen-
tial set of internal and lineal truncations on both monomers, the
authors were able to identify within the N-extension domain of
LdTopIS a conserved heptapeptide motif (RPPVVRS), which is spa-
tially close enough to interact with a region (amino acids 525–581)
of the large LdTopIL subunit. Remarkably, the pentapeptide RPPVV
introduces a loop in the secondary structure of LdTopIS that per-
mits the interaction with the large subunit. These results agree
well with those reported by Stewart and co-workers (1999), who
reconstituted enzyme species from hTopIB fragments that lack
the linker domain and observed that any alteration on this region
produces modiﬁcations in the religation step and an impairment
to be poisoned by Top inhibitors (Ireton et al., 2000; Fiorani
et al., 2003).
TopIB are nucleus-operating enzymes that need to display rec-
ognizable Nuclear Localization Signals (NLS) for nucleo-cytoplas-
mic trafﬁcking. Three NLS motifs have been recently identiﬁed in
LdTopIB by sequential deletion analyses of the genes encoding
the two subunits fused to the GFP-encoding ORF (Prada et al.,
2013b). NLS1 is located at the C-terminal extension of LdTopIL
and consists of a 44-amino acids region enriched in Lys residues
(easily identiﬁable by nuclear importins). NLS2 and NLS3 are
located at the N-terminal and C-terminal domains of the small
LdTopIL subunit, respectively. NLS2 is a well-identiﬁed 10-amino
acids signature preceding a well-conserved cluster of Ser in trypan-
osomatids. This fact is important since this NLS requires at least
one Ser residue to be functional; suggesting that hypothetical
phosphorylation of Ser is necessary for nuclear localization (Teng
et al., 2011). Finally, NLS3 is a 28-amino acid region that includes
the catalytic Tyr222. The amino acid sequence of NLS3 bears no
resemblance at all to other canonical NLS signals described so
far. However, it looks like the PY-NLSs signals proposed by Lee
and co-workers (2006) in human proteins, where proximal Pro
and Tyr residues are recognized by a b-importin to drive the pro-
tein inside the nucleus. Furthermore, regardless previous results
(BoseDasgupta et al., 2008), it was demonstrated that both sub-
Fig. 1. Schematic lineal representations of TopIB, TopII and TopIII from tritryps compared to human counterparts. (A) Human (top) and bisubunit L. donovani (down) TopIB,
structural domains: Non-conserved hydrophilic N-terminal domain (Nt); central ‘‘core’’ domain with the representative active site amino acids (‘‘tetrad’’); non-conserved
‘‘linker’’ subdomain that connects ‘‘core’’ and the C-terminal domain and C-terminal domain (Ct) containing the DNA cleaving Tyr (red strip). (B) Human (top) and L. donovani
TopII a (down) structural domains: N-terminal domain containing the ATPase and transducer domains; the Mg2+ binding site at the TopRim motif; a DNA binding that
contains the DNA cleaving Tyr (red strip); C-terminal domain. (C) Human (top) and T. brucei TopIII a (down) structural domains: N-terminal domain containing the Mg2+
binding site at the TopRim motif; the ATPase domain and C-terminal domain; DNA binding site that contains the DNA cleaving Tyr (red strip); Znf-C4 (zinc-ﬁnger domain).
Distances represented in the drawings are not in scale. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)
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et al., 2013b). Although some authors pointed to dual nucleus/
kinetoplast LdTopIB localization, no speciﬁc mitochondrial locali-
zation signals have been identiﬁed in any of the subunits of the
dimer. In addition, none of the chimeras fused to GFP co-localize
with kDNA, thus proving that none of LdTopIB subunits are bound
to DNA minicircles, which in fact rules out the hypothesis of a
TopIB operating in the kinetoplast (Das et al., 2006a,b).
2.2. Type II topoisomerases
Type II topoisomerases (Top II) are ubiquitous and essential
enzymes required for the regulation of DNA topology (Buck and
Zechiedrich, 2004). Top II are multimeric enzymes that hydrolyze
ATP to generate transient phosphotyrosine bonds at the 50 end of
both broken strands of the DNA helix. After cutting, the ends of
the DNA are separated and another DNA duplex is passed through
this break, which is ﬁnally religated (reviewed in Berger et al.,
1996; Wang, 1996; Champoux, 2001).
Type II enzymes are organized into two families, Top IIA and IIB.
The former includes, among others, the homodimeric (A2) eukary-
otic Top II, which relaxes positively supercoiled DNA. Type IIB
topoisomerases are heterotetrameric (A2B2) enzymes that only
include one family member, topoisomerase VI. Although its roleis less understood, it shares several features with the bacterial type
IIA topoisomerase (reviewed in Nitiss, 2009).
Eukaryotic Top II enzymes participate in the segregation and
maintenance of the chromosome structure (Gasser et al., 1986;
Rose et al., 1990) and are involved in chromosome condensation
and decondensation events (Adachi et al., 1991). In trypanosomat-
ids, besides the essential role in DNA nuclear metabolism Top II are
also important for the segregation, replication, remodeling and
maintenance of kDNA (Shapiro, 1994; Shapiro and Showalter,
1994; Lindsay et al., 2008). Mitochondrial TopII (mtTopII) is of par-
amount importance to disaggregate kDNA network during cell
division in kinetoplastids previous to cell division (Jensen and
Englund, 2012). Early studies carried out with the antitumour drug
etoposide in T. brucei, showed that replication of free minicircles
was disrupted by the drug, giving rise to multiple interlocked mini-
circle-dimers that contained newly synthesized DNA (Shapiro
et al., 1989). In fact, a loss in kDNA network (diskinetoplasty)
and subsequent cell death was reported upon the induction of an
RNAi-mediated silencing event in mtTop II, a phenomenon that
was preceded by a gradual shrinkage of the network and accumu-
lation of gapped free minicircle replication intermediates (Wang
and Englund, 2001). There are other likely functions for mtTopII,
such as the mending of kDNA after releasing minicircles for repli-
cation and the reattachment of nicked or gapped minicircles to the
R. Balaña-Fouce et al. / International Journal for Parasitology: Drugs and Drug Resistance 4 (2014) 326–337 331periphery of the replicating network (Lindsay et al., 2008), where a
type I Top enzyme could also play a critical role (Scocca and
Shapiro, 2008).
Only one mtTop II, localized primarily to the antipodal sites of
the kinetoplast (Melendy et al., 1988), is predicted after the analy-
sis of the genome sequence of several trypanosomatids (Strauss
and Wang, 1990; Fragoso and Goldenberg, 1992; Das et al., 2001;
Hanke et al., 2003; De Sousa et al., 2003). In addition, two other
Top II enzymes, which are encoded by the tandemly-linked sin-
gle-copy genes Top II a and Top II b, were found in the chromo-
some 11 of T. brucei (Kulikowicz and Shapiro, 2006). These Top II
(74% identical and differing only in the C-terminal region) share
a common node with other nuclear topoisomerases. The latter
are clearly different from the clade that includes the mtTop II,
which is positioned near the DNA gyrase branch that is more clo-
sely related to the prokaryotic type II enzymes. RNAi-mediated
silencing of the ATP-dependent nuclear Top II a in T. brucei caused
abnormalities in nuclear DNA and cell growth arrest at early stages
of cell cycle, pointing to this protein as an attractive therapeutic
target (Wang and Englund, 2001). Although the localization and
function of the putative Top II b protein is unknown, it is phyloge-
netically related to other eukaryotic nuclear Top II (Kulikowicz and
Shapiro, 2006). These researchers produced knock-down mutants
in the gene encoding TbTopII b showing that there was no detect-
able effect on growth rate, remaining its function in trypanosomat-
ids still unclear.
Regarding other trypanosomatids, a single ortholog of Top II a b
(but not of TopII b) is present in the L. major chromosome 28.
Although two additional ORFs were found in T. cruzi, they appeared
to be alleles of the same gene rather than a and b isoforms of Top II
(Kulikowicz and Shapiro, 2006).
Top IIA activity has been puriﬁed from several trypanosomatids
and some of the corresponding coding genes have been cloned
from Crithidia fasciculata (Shlomai and Zadok, 1983; Melendy
et al., 1988; Melendy and Ray, 1989; Pasion et al., 1992; Hines
and Ray, 1997), T. brucei (Strauss and Wang, 1990; Wang and
Englund, 2001; Kulikowicz and Shapiro, 2006), T. cruzi (Douc-
Rasy et al., 1986; Fragoso et al., 1998), Trypanosoma equiperdum
(Shapiro, 1994), L. donovani (Chakraborty and Majumder, 1987,
1991; Das et al., 2001), Leishmania chagasi (De Sousa et al., 2003)
and L. infantum (Hanke et al., 2003).
Basically, trypanosomatids TopII a are homodimeric proteins,
each subunit ranging in size from 137 to 160 kDa. Similarly to
other eukaryotes, each subunit is constituted by the fusion of
domains from bacterial DNA gyrase (GyrB and GyrA) and TopIV
(ParE and ParC) building a GyrB/ParE fused-domain at the N-termi-
nal-end and a GyrA/ParC fused-domain at the C-terminal-end,
respectively (Champoux, 2001).
Three structural domains, namely ATPase, central DNA binding
(B0 and A0), and C-terminal domain, which are present in a single
polypeptide chain, constitute eukaryotic Top II. These domains
are connected to each other by a ﬂexible hinge region (Sengupta
et al., 2003). The ATPase domain is found at the enzyme N-terminal
end, which spans the ﬁrst 489 amino acids in T. brucei and the ﬁrst
384 amino acids in L. donovani (Sengupta et al., 2005a,b). ATP bind-
ing to the nucleotide-binding cassette promotes the dimerization
of the N-terminal ATPase domains, which control the open/close
movements of the protein that are involved in DNA releasing
(Wei et al., 2005). Following the ATPase domain the core region
comprises the B0 domain (Toprim or unusual Rossman fold that
contains the constant Asp-X-Asp motif and coordinates two Mg2+
ions per each subunit) (Aravind et al., 1998) and the N-terminal
region of A0 (a central heart-shaped DNA-binding core), the latter
containing the catalytic Tyr residue involved in the trans-esteriﬁ-
cation reaction of DNA (Bjergbaek et al., 2000). The transducer heli-
cal domain, which links the ATPase domain to B0, is believed tocommunicate the nucleotide state of the ATPase domain to the rest
of the protein (Bendsen et al., 2009). Finally, after the A0 domain,
eukaryotic Top II have an unconserved C-terminal hydrophilic
domain that is dispensable for topoisomerization, although it plays
in L. donovani an important role in the in vitro TopII cleavage reac-
tion (Das et al., 2006b). In addition, this domain may also include
signals for nuclear localization and interaction with other proteins
(Reece and Maxwell, 1991). In fact, a potent nuclear localization
signal was found within the C-terminus of the L. donovani Top II
(Sengupta et al., 2003) (Fig. 1B).
In general, Top II are ATP-dependent enzymes that require the
presence of Mg2+ ions to fulﬁll their catalytic cycle (Bates and
Maxwell, 2007). Mg2+ ions seem to facilitate the interaction
between the enzyme and substrate in at least two ways: (i) facili-
tating the formation of TopII/DNA cleavage complexes; (ii) forming
the ATP-Mg2+ substrate required for ATPase activity (Sissi and
Palumbo, 2009). As it was indicated above, Top II contain the con-
served Mg2+-interaction domain called Toprim. Since Top II per-
form two sequential phosphoryl transfer reactions that promote
profound conformational enzymatic changes, the high afﬁnity of
Toprim for Mg2+ may be related to the need to keep the free 30-
OH end produced by the cleavage reaction strongly connected to
the Toprim acidic sequence, hence in place to perform religation
(Zhu et al., 1997).
2.3. Type IA topoisomerases
Subfamily Top IA differs in structure, sequence and catalytic
mechanism from TopIB. TopIA enzymes are essentially DNA relax-
ing enzymes (relaxases) introducing changes in negatively super-
colied DNA in discrete numbers (Lk in multiples of 1) (Byrd and
Matson, 1997). However, TopIII enzymes appear to be more active
catenating/decatenating DNA (decatenases) due to a speciﬁc 17-
amino insertion located close to the central cavity within the
enzyme (Li et al., 2000; Forterre et al., 2007; Viard and Bouthier,
2007). Trypanosomatids have a full set of TopIA subfamily
enzymes compartmentalized both in the nucleus and kinetoplast.
The T. brucei genome contains three type IA topoisomerase-encod-
ing genes: one in chromosome 10 (annotated as true TopIA) and
two in chromosome 11, both annotated as TopIII (http://www.ge-
nedb.org/genedb/tryp). For its part, L. major Friedlin has a putative
TopIA-encoding gene in chromosome 21 and two putative TopIII
ORFs at chromosomes 28 and 36, respectively. A similar composi-
tion of putative TopIA orthologous genes is deposited in the T. cruzi
genome database.
Trypanosomatid TopIA along with mtTopII are mitochondrial
enzymes that play a role in kDNA minicircles segregation during
cell division. Unlike TopIB, the catalytic tyrosine establishes the
transient phosphotyrosine intermediate bond at the 50-end of the
scissile DNA strand (Champoux, 2001). Structurally T. brucei TopIA
(TbTopIA) was characterized as an 88.9 kDa-monomeric protein
encoded by a gene of 2418 bp with a high degree of phylogenetic
conservation. The L. donovani ortholog consists of a protein of 90
kDa encoded by an ORF of 2453 bp. TbTopIA contains an N-termi-
nal domain, which has a mitochondrial localization signal that
drives the protein to kDNA, followed by a phylogenetically con-
served region similar to prokaryotic TopIA called core (Scocca
and Shapiro, 2008). This region contains all the conserved domains
of the protein with two DNA binding topofolds (amino acids 186–
660) (Duguet et al., 2006) and a C-terminal end variable in size and
sequence. Four structural domains constitute the core region that
give rise to a toroidal-shaped protein with a central motif ﬁlled
of basic amino acids that allows the passage of a single- or dou-
ble-stranded DNA molecule (Duguet et al., 2006). Between
domains II and IV a hinge motif allows two spatial open and close
conﬁgurations. TbTopIA has the catalytic Tyr-362 residue within
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acids named toprim (amino acids 10–170), which is involved in
the conformational changes of the protein during the relaxation
reaction. Unlike prokaryotic TopIA proteins, TbTopIA lack Zn-bind-
ing domains (Scocca and Shapiro, 2008).
Immunolocalization assays clearly demonstrated that mtTbT-
opIA operates inside the single mitochondrion of T. brucei linked
to ﬂagellar basal body and associated to the enzymes in charge
of DNA replication (SSE-1, PIF5, Pol b, ligase b and mtTopII) at
the antipodal sites of kDNA disc (Jensen and Englund, 2012). These
studies showed that the position of mtTbTopIA is changing from
one pole to the other pole of the kDNA disk as replication is taking
place. Silencing studies of mtTbTopIA by RNAi under tetracycline
control, showed that after induction with the antibiotic, growth
arrest and almost a complete disappearance of the kDNA occurred
with no changes in nuclear DNA (Scocca and Shapiro, 2008). A dee-
per analysis of minicircle network replication after RNA silencing
showed an accumulation of late theta forms but not of daughter
catenates, suggesting that mtTbTopIA plays a role in the resolution
on the entwined parental strands during the resolution step of
minicircle replication (Scocca and Shapiro, 2008). Finally, late free
minicircles containing gaps are used by mitochondrial TopII
enzymes to reattach them to the replicating kDNA network
(Wang, 2002). Since mitochondrial trypanosomatid TopIA has no
orthologs in the deﬁnitive host, and as a result of the deadly effects
that its abolition has (as described above), there is no doubt that
this enzyme is an ideal target to be explored for the development
of novel drugs (Tang and Shapiro, 2010).
Top III are TopIA subfamily proteins, which in turn are subdi-
vided into TopIII a and TopIII b isoforms (Viard and Bouthier,
2007). Trypanosomatids contain phylogenetically well-conserved
genes encoding both TopIII a and TopIII b (Kim and Cross, 2010).
Genetic analysis revealed the presence of a 2754-bp ORF encoding
the 102.5-kDa T. brucei TopIII a (TbTopIII a) and a putative 2523-
bp ORF encoding the 937-kDa T. brucei TopIII b (TbTopIII b) (Kim
and Cross, 2010). Similarly, the putative gene encoding L. donovani
TopIII a (LdTopIII a) is 2844 bp long and encodes a 104-kDa mono-
mer, whereas the 2601-bp gene encoding TopIIIb (LdTopIII b) pro-
duces a 95-kDa protein (http://www.genedb.org/Homepage/
Ldonovani_BPK282A1). The deduced amino acid sequence of LdTo-
pIII b has the active Tyr at position 327, which is located within a
highly conserved GYISYPRTES signature. This protein contains
seven CXXC sequences instead of the eight motifs found in other
TopIIIb proteins (Banerjee et al., 2011). In a similar way, TbTopIII
a has been characterized and contains a Zn-binding domain at
the C-terminus. The sequences of tritryps TopIIIa are very well
conserved in T. brucei, T. cruzi and L. major and contain Zn-binding
motif(s) at their C-terminal regions. A LdTopIII b fused to GFP chi-
mera was used to identify the localization of this protein, revealing
that LdTopIIIb is targeted inside both the parasite nucleus and
kinetoplast (Banerjee et al., 2011) (Fig. 1C).
TopIII proteins show decatenase rather than relaxase activity by
their own. TopIII a proteins play a role in concert with RecQ heli-
cases maintaining genomic stability and integrity by controlling
recombination events (Kim and Wang, 1992). TbTopIII a acts as a
single-stranded DNA decatenase and release non-crossover prod-
ucts resulting from the dissolution of recombinogenic structures,
such as double Holliday junctions. Regarding other eukarya organ-
isms, TbTopIII a may be part of a putative RecQ-TopIII-Rmi1 (RTR)
complex that is involved in the recombination-mediated antigenic
switching in T. brucei, removing undesirable recombination inter-
mediates (Yang et al., 2010; Knoll et al., 2014). Null-TbTopIII a
mutants have been shown to play a critical role in homologous
recombination processes and antigenic switching. Double replace-
ment of the two alleles encoding the TbTopIII a produces no
changes in the proliferation rate of the parasites, but generatesan elevated frequency of recombinant events and hyper-switcher
phenotype always linked to RAD51. These experiments concluded
that TopIII a plays a crucial role in homologous recombination pro-
cesses and is closely linked to adaptive VSG switching that allows
blood forms of T. brucei to evade from the host immune response
(Kim and Cross, 2010).
Very few studies have been carried out with TopIII b enzymes in
trypanosomatids. Although TopIII b is not essential for cell survival,
null-mutants display unique phenotypes in eukarya. Knock-out
mice lacking the TopIII b -encoded gene develop normally up to
maturity, but have a shorter lifespan and exhibit decreased fertility
(Kwan and Wang, 2001; Kwan et al., 2003). In addition, these
mutants have a deﬁcient activation of p53, pointing to an impor-
tant role of TopIIIb in apoptosis induced by DNA damage
(Mohanty et al., 2008). Deﬁcient b top3 mutant yeasts are viable
but display a slow-growth phenotype (Gangloff et al., 1999). Exper-
iments with the LdTopIII b gene, showed a partial recovery of phe-
notype (Banerjee et al., 2011). In addition, this property is lost
when rescuing is produced by a partially deleted ORF lacking the
Zn-binding domain of the protein. However, no experiments
regarding genome stability and programmed cell death have been
performed in trypanosomatids, thus the role of this enzyme
remaining a mystery in these parasites.3. DNA topoisomerases as potential drug targets
Both TopIB and TopII are validated targets for antineoplastic
drugs in human medicine. TopIB inhibitors, such as topotecan (a
water soluble derivative of CPT) and irinotecan (Camptosar) – a
prodrug that must be processed hydrolytically by intracellular
esterases – are currently in clinical use against ovarian carcinoma
(Wethington et al., 2008) and colorectal cancer, respectively
(Kuppens et al., 2004). On the other hand, TopII inhibitors are also
part of the antitumour drug Vademecum, such as the epipodo-
phyllotoxin derivatives (etoposide and teniposide) (Hande, 1998)
or acridine analogues (amsacrine, doxorubicin, etc.) (Louie and
Issell, 1985). Last but not least, the bacterial DNA gyrase has been
used for years as a target for a number of antibiotics of the ﬂuoro-
quinolone family (Drlica and Malik, 2003).
Top inhibitors are classiﬁed into two categories: (i) Class I or
enzyme poisons are those compounds that displace the cleaving/
ligation balance toward cleavage, thus stabilizing the cleavage
complexes with DNA. This selectively kills the cells found in S
phase by collision with the advancing replication fork during
DNA replication (Tsao et al., 1993); (ii) Class II or ‘‘true inhibitors’’
are those compounds that interfere with the catalytic functions of
the enzyme without trapping the covalent complexes (Pommier,
2006).
With this favourable background, the opportunity to explore
these enzymes as potential drug targets in trypanosomatids was
early underlined, even when their molecular structures had not
yet been described (Burri et al., 1996; Cheesman, 2000). The pres-
ence of decatenase and relaxase activities in the single mitochon-
dria of these parasites and their role on the structure of the
kinetoplast minicircle network, pointed to these enzymes as extre-
mely attractive targets to design speciﬁc drugs to deconstruct
kDNA. In 1995 the group led by Shapiro showed that CPT and eto-
poside triggered kDNA linearization and further disappearance in
T. brucei, a phenomenon called diskinetoplasticity, which led to
parasite death within hours (Bodley and Shapiro, 1995).
With the exception of yeast, TopIBs are essential for eukaryotic
organisms (Uemura et al., 1987). Double gene replacement of the
gene encoding LdTopIS, originates a non-viable phenotype in L.
major (Balaña-Fouce et al., 2008). In addition, gene silencing of
each of the T. brucei TopIB subunits, results in a drastic reduction
Table 2
TopIB inhibitors assayed in trypanosomatids.
Class TopIB inhibitors Trypanosomatid References
Camptothecins CPT, SN38, topotecan, gimatecan L. infantum Prada et al. (2013a)
CPT, irinotecan, topotecan T. brucei Bodley and Shapiro (1995)
Deterding et al. (2005)
Indocarbazoles Rebeccamycin T. brucei Deterding et al. (2005)
Napthoquinones Diospyrin
diospyrin, naphthalene derivatives
L. donovani
T. brucei, T.cruzi
Hazra et al. (1987)
Ray et al. (1998)
Ganapaty et al. (2006)
Flavonoids Baicalein, luteolin, quercetin L. donovani Das et al. (2006a,b)
Poliheterocyclis Berberin L. braziliensis
L. donovani
T. brucei, T. congolense
Vennerstrom et al. (1990)
Marquis et al. (2003)
Merschjohann et al. (2001)
Pentavalent antimony Pentostam, glucantime L. donovani Chakraborty and Majumder (1988)
Indenoisoquinolines Indotecan, AM 13-55
alkylamine N-6, N-6 3-aminopropyl,
N-6 3-imidazolylprolyl
L. infantum
T. brucei
Balaña-Fouce et al. (2012)
Bakshi et al. (2009)
Bis-benzimidazoles Hoechst-33258, Hoechst-33342 L. donovani Walker and Saravia (2004)
Triterpenoids Betulinic acid and derivatives
dihydrobetulinic acid
L. donovani, L. amazonensis,
L. braziliensis, T. cruzi
L. donovani
Domínguez-Carmona et al. (2010)
Chowdhury et al. (2003)
Insaturated fatty acids 6-Heptadecynoic acid and 6-icosynoic acid
(±)-17-methyltrans-4,5-methyleneoctadecanoic acid
2-Alkynoic fatty acids
L. donovani Carballeira et al. (2009)
Carballeira et al. (2010)
Carballeira et al. (2012)
Lignan glycosides Lyoniside, sacaroside L. donovani Saha et al. (2013)
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These ﬁndings and the structural differences from host orthologs
pointed to these enzymes as putative targets for drug discovery
(Balaña-Fouce et al., 2006). First, the uncompetitive inhibitor CPT
and its derivatives have been used as inhibitors against T. brucei
and Leishmania spp. TopIB with promising results (Das et al.,
2004). The primary effect of the formation of single strand breaks
(SSBs) can lead to the induction of the TDP1 repair system enzyme
studied by Pommier in mammalian cells (Dexheimer et al., 2008)
and recently described in trypanosomatids (Banerjee et al., 2010).
The collision of the replication fork during DNA replication trans-
forms SSBs into irreversible double-stranded DNA breaks (DSBs),
which can be repaired only by homologous DNA recombination
mechanisms. The persistence of no repaired DSBs may cause a pro-
cess of programmed cell death both in amastigotes and promastig-
otes, which has been described in detail as a result of the exposure
of L. donovani to Top poisons (Sen et al., 2004).
In addition to CPT, topotecan and Camptosar were experimen-
tally tested against ex vivo cultures of experimentally infected
murine splenocytes with L. infantum amastigotes, showing thatTable 3
TopII inhibitors assayed in trypanosomatids.
Class TopII inhibitors
Fluoroquinolones Norﬂoxacin, ciproﬂoxacin, oﬂoxacin
Ciproﬂoxacin, enoxacin
Norﬂoxacin, oﬂoxacin
Podophylotoxins Etoposide, teniposide
Ellipticines 2-Methyl-9-OH-ellipticin
Flavonoids Baicalein, luteolin, quercetin
Anthracyclins Doxorrubicin
Diamidines Pentamidine
Aminocoumarins Novobiocin
Acridines Anilinoacridines
Triterpenoids Dihydrobetulinic acidgimatecan, an orphan drug approved by the European Medicines
Agency for the treatment of glioblastoma (Hu et al., 2013), has a
strong leishmanicidal activity and good selective index (Prada
et al., 2013a). An interesting group of non-CPT TopIB poisons are
indenoisoquinolines, which were initially developed as antitumour
compounds with an improved ability to stabilize cleavage com-
plexes (Antony et al., 2005). Some of these compounds have shown
interesting therapeutic proﬁles against L. infantum and T. brucei in
experimental infections of mice (Bakshi et al., 2009; Balaña-Fouce
et al., 2012). Indotecan, administered intraperitoneally every 2
days for 15 days (a total of eight doses) had a similar cure rate that
paromomycin alone or in combination with 200-mg/kg-body-
weight Glucantime in experimental infections of VL in BALB/c mice
(Gangneux et al., 1997). Furthermore, indotecan was more effec-
tive than the same dose schedule of CPT either free or liposome
encapsulated, in a murine model of L. donovani leishmaniasis
(Proulx et al., 2001). Some naturally occurring molecules have
shown to be TopIB poisons and have anti-leishmanial effects.
Amongst others, the bisnapthaquinone dyospirin (Ray et al.,
1998), the pentacyclic triterpenoid dihydrobetulinic acidTrypanosomatid References
T. brucei Nenortas et al. (1999, 2003)
L. panamensis Cortazar et al. (2007)
T. cruzi Gonzales-Perdomo et al. (1990)
L. donovani Sengupta et al. (2005a,b)
T. equiperdum Shapiro and Showalter (1994)
T. equiperdum Shapiro et al. (1989)
L. donovani
L. panamensis
Tasdemir et al. (2006)
Mittra et al. (2000)
Cortazar et al. (2007)
L. donovani Singh and Dey (2007)
L. donovani
L. panamensis
Singh and Dey (2007)
Cortazar et al. (2007)
T. cruzi
L. donovani
Gonzales-Perdomo et al. (1990)
Singh et al. (2005)
L. chagasi
T. brucei
Werbovetz et al. (1992)
Gamage et al. (1997)
L. donovani Chowdhury et al. (2003)
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lein, luteolin and quercetin) are potent LdTopIB poisons in vitro
(Mittra et al., 2000; Das et al., 2006a,b). For their part, unsaturated
fatty acids frommarine organisms have shown to be selective Class
II inhibitors of recombinant L. infantum TopIB (Carballeira, 2013)
(Table 2).
Similarly to TopIB, TopII silencing in T. brucei, leads to the pro-
gressive degradation of kDNA network and parasite death (see
above). Eukaryotic TopII was proposed as a putative target for
anti-parasitic drugs since the 1990s (Burri et al., 1996;
Cheesman, 2000). One of the ﬁrst groups of compounds that
showed therapeutic potential against trypanosomatids was
derived from the 9-anilinoacridine backbone, and had potential
anti-tumour activity owing to TopII inhibition (Werbovetz et al.,
1994). Linearization of kDNA minicircles has also been reported
in parasites treated with these compounds because of TopII inhibi-
tion, preventing the growth of L. major promastigotes and amastig-
otes (Gamage et al., 1997). Epipodophyllotoxins are semisynthetic
derivatives of non-alkaloid toxins from the root extracts of plants
from the genus Podophyllum (Table 3). The two leading com-
pounds, etoposide and teniposide, stabilize the double-stranded
cleavage mediated by TopII and inhibit the religation of DNA
breaks (Yang et al., 2009). These compounds are clinically in use
against different types of cancer (Anonymous, 2000), and have
been proven effective against different parasites (García-Estrada
et al., 2010), inducing apoptotic-like cell death (Meslin et al.,
2007). However, etoposide have not shown any effect on trypano-
somatids, pointing to important structural differences between
this enzyme and that from the host counterpart (Sengupta et al.,
2005a,b).
4. Concluding remarks
Trypanosomatids have a complete set of six classes of Top
enzymes encoded in their respective genomes. Each class, deﬁned
by structure and mechanism of action, has distinct but sometimes
overlapping cellular localizations and functions. TopIB enzymes are
structurally dissimilar to the rest of proteins described so far, but
they conserve the ability to pass a single DNA strand in a proces-
sive manner to relief torsional stress. TopIA, including TopIII a
and TopIII b enzymes have decatenase rather than relaxase activity
and work in concert with helicases to resolve noncrossover prod-
ucts by dissolution of recombination intermediates. TopII enzymes,
both nuclear and mitochondrial, carry out strand passage through
a double-strand break, including decatenating and unknotting
activities and are key enzymes in kDNA replication. TopIB and
TopII are important targets for drug intervention in cancer. Many
of the drugs used as antitumourals have been used in a ‘‘piggy
backing’’ strategy against tritryps with different success. A full
structural knowledge of tritryps Top proteins based on 3D X-ray
analysis of Top crystals, will allow in silico high-throughput virtual
screening of potential inhibitors in a structure-based drug discov-
ery strategy.
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